GSK EBITDA 2010-2022 | GSK

GSK annual and quarterly EBITDA history from 2010 to 2022. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
  • GSK EBITDA for the quarter ending September 30, 2022 was $2.425B, a 39.56% decline year-over-year.
  • GSK EBITDA for the twelve months ending September 30, 2022 was $10.395B, a 30.9% decline year-over-year.
  • GSK 2021 annual EBITDA was $8.527B, a 34.47% decline from 2020.
  • GSK 2020 annual EBITDA was $13.012B, a 9.63% increase from 2019.
  • GSK 2019 annual EBITDA was $11.869B, a 21.16% increase from 2018.
GSK Annual EBITDA
(Millions of US $)
2021 $8,527
2020 $13,012
2019 $11,869
2018 $9,796
2017 $7,744
2016 $5,925
2015 $18,275
2014 $8,756
2013 $12,606
2012 $13,437
2011 $15,216
2010 $9,052
2009 $15,183
GSK Quarterly EBITDA
(Millions of US $)
2022-09-30 $2,425
2022-06-30 $2,089
2022-03-31 $4,703
2021-12-31 $1,179
2021-09-30 $4,013
2021-06-30 $3,276
2021-03-31 $2,832
2020-12-31 $4,922
2020-09-30 $3,179
2020-06-30 $2,083
2020-03-31 $2,828
2019-12-31 $2,405
2019-09-30 $3,177
2019-06-30 $2,886
2019-03-31 $3,401
2018-12-31 $2,323
2018-09-30 $3,096
2018-06-30 $1,311
2018-03-31 $3,067
2017-12-31 $439
2017-09-30 $3,396
2017-06-30 $1,378
2017-03-31 $2,532
2016-09-30 $2,014
2016-06-30 $360
2016-03-31 $1,835
2015-12-31 $13,767
2015-09-30 $3,349
2015-06-30 $61
2015-03-31 $1,167
2014-12-31 $1,061
2014-09-30 $1,983
2014-06-30 $2,401
2014-03-31 $2,747
2013-12-31 $3,037
2013-09-30 $3,862
2013-06-30 $2,988
2013-03-31 $3,037
2012-12-31 $4,093
2012-09-30 $3,274
2012-06-30 $3,016
2012-03-31 $3,379
2011-12-31 $4,525
2011-09-30 $4,033
2011-06-30 $3,546
2011-03-31 $2,960
2010-12-31 $617
2010-09-30 $3,967
2010-06-30 $-551
2010-03-31 $3,796
2009-12-31 $4,021
2009-09-30 $4,264
2009-06-30 $3,800
2009-03-31 $3,251
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $68.515B $46.910B
GSK plc is a biopharma company. Its vaccine portfolio protects people from meningitis, shingles, flu, polio, measles and many more. GSK plc, formerly known as GLAXOSMITHKLINE, is based in Brentford, the United Kingdom.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $168.264B 10.27
Bio-Rad Laboratories (BIO.B) United States $11.666B 27.68
QIAGEN (QGEN) Netherlands $11.104B 18.95
Ginkgo Bioworks Holdings (DNA) United States $3.534B 0.00
Myovant Sciences (MYOV) United Kingdom $2.599B 0.00
Arcus Biosciences (RCUS) United States $1.967B 29.53
Biohaven (BHVN) United States $1.050B 0.00
Emergent Biosolutions (EBS) United States $0.590B 4.64
Zymeworks (ZYME) Canada $0.506B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.282B 0.00
Enzo Biochem (ENZ) United States $0.096B 0.00
SQZ Biotechnologies (SQZ) United States $0.077B 0.00
Gelesis Holdings (GLS) United States $0.030B 0.00
Ambrx Biopharma (AMAM) United States $0.019B 0.00